Connor, Clark & Lunn Investment Management Ltd. Krystal Biotech, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$22 Billion
Q2 2024

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$108.01 - $179.35 $247,990 - $411,787	2,296 New	2,296 $408,000
Q2 2023 Aug 10, 2023	BUY	$78.48 - $130.32 $5,179 - $8,601	66 Added 0.94%	7,056 $828,000
Q1 2023 May 09, 2023	SELL	$72.39 - $84.27 $695,016 - $809,076	-9,601 Reduced 57.87%	6,990 $559,000
Q4 2022 Feb 10, 2023	SELL	$63.14 - $79.9 $498,111 - $630,331	-7,889 Reduced 32.23%	16,591 $1.31 Million
Q3 2022 Nov 10, 2022	BUY	$64.85 - $82.4 $1.38 Million - $1.75 Million	21,278 Added 664.52%	24,480 $1.71 Million
Q2 2022 Aug 05, 2022	BUY	$48.93 - $73.47 $156,673 - $235,250	3,202 New	3,202 $210,000
Q1 2022 May 12, 2022	SELL	$51.99 - $72.11 $591,178 - $819,962	-11,371 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$39.81 - $88.24 $452,679 - $1 Million	11,371 New	11,371 $795,000

Others Institutions Holding KRYS

# of Institutions

266

Shares Held

25M

Call Options Held

270K

Put Options Held

172K

Black Rock Inc. New York, NY

3.95M
Shares

$718 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

2.87M
Shares

$522 Million
0.01% of portfolio
Avoro Capital Advisors LLC New York, NY

2.43M
Shares

$442 Million
6.1% of portfolio
State Street Corp Boston, MA

1.33M
Shares

$242 Million
0.01% of portfolio
Redmile Group, LLC San Francisco, CA

1.02M
Shares

$186 Million
12.22% of portfolio

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.67B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account